CRSP
Crispr Therapeutics Ag Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$51.42Close
$4.9BMarket cap
$44.34 – $63.9952-week range
Nov 9, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 40 · weaker than 60% of stocks over 12 months
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
20%
1wk
up 4.1%
price change
1mo
down 7.0%
price change
12-month return
down 16%
market up 11% ·
its own down 29%
F-score
—
— Not assessed
Altman Z
7.42
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.6×
price / book
Earnings yield
down 14.5%
EBIT / enterprise value
Cheaper than
26%
of the market · expensive
Revenue growth
down 91%
year on year
EPS growth
—
latest quarter
Sales growth
up 1041%
latest quarter · +973 pts
ROE
down 30%
return on equity
Free cash margin
down 9855%
-$345.9M FCF
D/E
0.00
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.2%
$2.66 a day · 2×ATR $46.10
RS
40 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.73
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: fails
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 11.8% over the year, from 86m to 96m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 90.6% over the year, from $37.3M to $3.5M.
Last reported
Aug 3, 2026
Results reaction
Aug 3, 2026+7% vs market2 sessions after results
Financials
- Net -16570%
- Free cash -9855%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $719,000 | $915.0M | $1.2M | $371.2M | $37.3M | $3.5M |
| Operating income | -$354.4M | $373.5M | -$673.2M | -$222.5M | -$466.6M | -$664.6M |
| Net income | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| Net margin | -48521% | 41% | -54272% | -41% | -982% | -16570% |
| Earnings per share | -$5.29 | $4.70 | -$8.36 | -$1.94 | -$4.34 | -$6.47 |
| Free cash flow | -$256.7M | $457.3M | -$532.9M | -$269.8M | -$144.7M | -$345.9M |
| Free cash margin | -35706% | 50% | -44485% | -73% | -388% | -9855% |
| Cash | $1.2B | $923.0M | $211.9M | $389.5M | $298.3M | $347.6M |
| Long-term debt | — | — | — | — | — | $0 |
| Shareholders' equity | $1.7B | $2.4B | $1.9B | $1.9B | $1.9B | $1.9B |
| Shares outstanding | 73.91m | 76.99m | 78.51m | 80.04m | 85.74m | 95.89m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 3, 2026 | Quarterly ↗ | Jun 30, 2026 | 34d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Feb 12, 2026 | Annual ↗ | Dec 31, 2025 | 43d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 4, 2025 | Quarterly ↗ | Jun 30, 2025 | 35d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 11, 2025 | Annual ↗ | Dec 31, 2024 | 42d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 5, 2024 | Quarterly ↗ | Jun 30, 2024 | 36d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 21, 2024 | Annual ↗ | Dec 31, 2023 | 52d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 19, 2026 | Director or officer change ↗ |
| Aug 3, 2026 | Results ↗ |
| Jun 4, 2026 | Director or officer change · Charter or bylaws · Shareholder vote ↗ |
| May 4, 2026 | Results ↗ |
| Mar 16, 2026 | Material agreement · New obligation · Unregistered share sale ↗ |
| Mar 11, 2026 | Other events ↗ |
| Feb 12, 2026 | Results ↗ |
| Jan 12, 2026 | Other events ↗ |
| Nov 10, 2025 | Results ↗ |
| Oct 15, 2025 | Other events ↗ |
| Aug 4, 2025 | Results ↗ |
| Jun 26, 2025 | Other events ↗ |